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ADULT UROLOGY
ELSEVIER
HIGH-ENERGY TRANSURETHRAL MICROWAVE 
THERMOTHERAPY: A THERMOABLATIVE TREATMENT FOR 
BENIGN PROSTATIC OBSTRUCTION
M. J. A. M. d e  WILDT, F. M. J. DEBRUYNE, a n d  J. J. M. C  H. d e  l a  ROSETTE
ABSTRACT
Objectives. High-energy transurethral microwave thermotherapy (TUMT) was developed to increase treat­
ment efficacy over former low-energy treatment protocols as an outpatient-based, anesthesia-free procedure 
for patients with benign prostatic obstruction. A Phase 1) study was conducted to evaluate treatment outcome 
and to enlighten possible prognostic factors.
Methods. Eighty-five patients with lower urinary tract symptoms were included in the study. A Madsen 
symptom score of 8 or more, a maximum flow less than 15 mL/s, and a postvoid residual urine volume (PVR) 
of under 350 mL were the main requirements for entry,
Results. Eleven patients were lost to follow-up, making 74 patients evaluable at 1 -year follow-up. Significant 
improvement was noticed in all indices: the Madsen symptom score improved 58% from baseline; the max­
imum flow rate improved from 9.4 to 14.9 mL/s, with a decrease in PVR of 80 mL to 25 mL; bladder outlet 
obstruction could be relieved in 78% of patients; and prostate volume decreased by 20%, with cavity for­
mation in 42% of patients. Patients with bigger prostates (greater than 40 cm3) and patients with more 
severe bladder-outlet obstruction appeared to be the best responders. Post-treatment morbidity consisted 
of a prolonged need for transurethral catheter drainage (mean 16 days), with correlated irritative voiding 
complaints for an average of 2 to 3 weeks.
Conclusions. Overall improvement of high-energy thermotherapy now shows comparable results to surgical 
resection of the prostate. UROLOGY 48: 416-423, 1996.
Benign prostatic obstruction (BPO) is a com­mon disease in men that is creating an increas­
ing demand on the health care system. It is esti­
mated that eventually one third of all men will 
require an operation for relief of lower urinary 
tract symptoms (LUTS) due to BPO.1
For more than 50 years, the treatment for BPO 
has been decreasing gland volume. The surgical 
removal of prostate tissue is still considered the 
reference standard, Besides being the m ost com­
monly performed surgical procedure in elderly 
men, it comprises a large part of the urologist's 
workload.2 Complications and side effects include 
infection, incontinence, retrograde ejaculation,
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urethral stricture, and  impotence. In addition, 
some patients have a severe medical illness that 
increases anesthetic and surgical risk, which may 
predispose them  to postoperative sepsis or a car­
diovascular event.3,4
Currently , the m anagem ent of BPO is u n d e r  
evaluation. M edical trea tm en t is becom ing an in ­
creasingly im portan t option  in pa tien ts  w ith  
m oderate LUTS.5,6 In  addition , several m in im ally  
invasive treatm ent op tions have been tested. The 
use of heat (app lied  by  different heat genera to rs  
such as u ltrasound , radio-frequency, laser, and  
microwave devices) appears to be the  m ost 
prom ising a lternative .7" 10 Of these d ifferent ap ­
plications, m icrow ave energy has been  m ost 
extensively investigated. C on tinuous develop­
m ents have led to tran su re th ra l m icrow ave th e r ­
m otherapy (TU M T) tha t m akes it possib le  to 
obtain h igh tem peratures deep inside the p ro s ­
tate lateral lobes w hile still p reserv ing  the  u re ­
thral mucosa; 1296-M Hz m icrow ave rad ia tio n  
is applied from a tran su re th ra l an tenna , and  the
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TABLE I. Inclusion and exclusion criteria for high-energy 
________ transurethral microwave thermotherapy treatment
Inclusion Criteria Exclusion Criteria
Age >  45  years
Prostatic urethra measured by 
flexible cystoscopy s  2.5 cm 
Madsen symptom score ^  8 
Qmax ^  15 mL/s
Postvoid residual volume ^  350  mL 
Voided volume s  100 mL
Acute prostatitis or urinary tract infection 
Prostate carcinoma (excluded by 
prosta te  biopsy)
Isolated obstructed  prostatic middle lobe
Diabetes mellitus
Intravesical pathology
Neurologic disorders
Drugs influencing biadder function
m ucosa  is s im ultaneously  cooled by circu lat­
ing  fluid w ith in  the applicator (P rosta tron  
device, T echnom ed  Medical Systems, Lyon, 
F ra n c e ) .  This concept allows an outpatient- 
based , anesthesia-free  p rocedure . Significant 
sym ptom atic  im provem ent and increase in  ob­
jective  param eters such  as m axim um  flow rates 
and  postvo id  residual u rine  volum e (PVR) are 
rep o rte d .10 The clinical im provem ent has been 
sh o w n  n o t to be due to a placebo effect or the 
resu lt of the  associated u re th ra l instrum enta tion  
in  random ized  trials of TUMT versus sham .11,12 
A lthough  in  a random ized  TUMT versus trans­
u re th ra l resection  of the prostate  (TU R P) trial 
the sym ptom atic  im provem ent is sim ilar to im ­
p ro v em en t seen after TURP, the objective im ­
p rovem en t is less p ronounced  and the durability 
of the trea tm en t is u n c lea r .13 Interstitial ther­
m om etry  s tud ies during  TUMT treatm ents have 
show n  tha t there is a strong correlation  between 
the trea tm en t outcom e and the obtained tem ­
pera tu res  w ith in  the p ro s ta te .14 This has led to 
the developm ent of a new software pro tocol that 
operates the P rosta tron  u n it (Prostasoft 2 ,5 ) ,  
enabling  h igher energy levels (in trap rosta tic  
tem pera tu res  up  to 75°C) w ith  an average in ­
crease of total energy delivered to the prostate of 
40%, thus creating tissue necrosis and cavity for­
m ation  w ith in  the prostate; this is term ed ther­
m o ab la tio n .15,16
W e conducted a Phase II study using this high- 
energy p ro to co l Besides docum enting treatment 
outcom e, we will also try to determine possible 
prognostic factors that contribute to the better re­
sults.
MATERIAL AND METHODS
Between October 1993 and August 1994, 85 patients were 
treated w ith  the Prostasoft 2.5 protocol approved by the hos­
pital's ethical committee. All 85 men, aged 50 to 85 years 
(m ean ±  SD 64.7 ±  8 .6 ) , had LUTS related to BPO and, in 
principle, were candidates for either TURP or an open pros­
tatectomy. Inclusion and exclusion criteria are mentioned in
Table 1.
Twelve patients ( 14%) were in poor cardiac or pulmonary 
health (ASA 3 to 4 ) .  At baseline, all patients underwent the 
following investigations: general history; complete physical 
examination with digital rectal examination (D RE); estima­
tions of full blood count, blood urea, and creatinine; and urine 
microscopy and culture. Urine cytology and prostate-specific 
antigen (PSA; Hybritcch) levels were always measured to ex­
clude coexisting malignancy. Upper urinary tract dilation and 
renal pathology were excluded by ultrasound investigation. 
Prostate configuration was assessed by performing transrectal 
ultrasonography with volume calculated by a planimetrie 
technique (TRUSP) (Kretz Cotnbison 330 with a 7,5-MHz 
iransrectal probe; multi-3D VRW 77AK). In case of an ab­
normality detected by DRE, PSA level, or TRUSP, ultrasound- 
guided prostate biopsies were performed. Flexible urethro- 
cystoscopy (S torz) was carried out to judge the patency of 
the (prostatic) urethra for the presence of strictures or an 
isolated obstructing prostatic middle lobe and to exclude in­
travesical pathology. Patient symptoms were evaluated using 
a physician-guided Madsen symptom score allowing compar­
ison with previous studies reporting on TUMT.17 In addition, 
the self-administered International Prostate Symptom Score 
(IP5S) was used.18
A Dantec Urodyn 1000 flowmeter was used to register the 
maximum flow rates (w ith corrections for (low artifacts, using 
the 2-second m ethod) and voided volume. Postvoid residual 
volume (estimated by suprapubic ultrasonography with an 
ellipsoid technique) and voiding percentage (that is, [voided 
volume {voided volume +  PVR}] X  100) as a measure of 
voiding efficiency were also recorded.
To quantify the grade of bladder-outlet obstruction, uro- 
dynamic investigation with pressure-flow (P Q ) analysis was 
performed, intravesical and rectal pressures were recorded us­
ing 8F catheters m ounted with mìcrotip-sensors (MTC, Dra­
ger, G erm any), and detrusor pressure was calculated as the 
difference between both. The digitally stored pressure and 
flow data were analyzed by a program developed at our de­
partm ent (UIC/BME Research Center, Department of Urol- 
ogy, Nijmegen, Netherlands). The following parameters de­
rived from the PQ analysis were used: detrusor pressure at 
maximum flow ( P ^  at Qmax in cm H¿0 ) ,  maximum flow 
rate (PQ-Qmax in m L /s ) , and the linearized passive urethral 
resistance relation (linPURR; obstruction grading according 
to Schäfer).14,20 A patient is considered urodynamically ob­
structed when Pt{cl at Qmax falls into the obstructed area of 
the linPURR nomogram when the linPURR is 3 or greater.
After correct positioning of the urethral heat applicaLor and 
rectal-temperature probe, a 60-minute microwave treatment 
was performed. A more extensive description of such a treat­
ment has been reported elsewhere.21 Two hours before treat­
ment, a 20 to 40 mg dose of m orphine sulfate was adminis­
tered orally. If necessary, additional intravenous sedation with
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Baseline 3 months 6 months 12 months
85 83 *  81 74
1 TURP elsewhere 
1 died of terminal heart 
failure (not treatment 
related)
1 died of pulmonary failure 
due to a r antitrypsine 
deficiency
1 refused further visits 
to outpatient clinics
FIGURE l. Follow-up scheme of the 85 patients at 12, 26, and 52 weeks.
3 TURP because  of 
unsatisfactory result
2 refused further visits to 
outpatient clinics 
1 died of metastasized 
gastrointestinal tumor 
1 I as  er-prostatectomy
F IG U R E  2. im provem ent o f  
baseline parameters after 4, 12, 
26, and 52 weeks. Parameters 
used: Madsen symptom score 
(points); International Prostate 
Symptom Score (points); Qmax 
(mL/s); postvoid residual (PVR) 
urine (x  10 mL).
Madsen IPSS Qmax (ml/s) PVR (x 10 ml)
FOLLOW UP IN WEEKS
a combination of diazepam and fentanyl was given when pa­
tients experienced major discomfort during treatment; this 
was mostly expressed as an intense urge to void, sometimes 
in combination with an urge to defecate. Initial experience 
showed urinary retention in nearly all patients; therefore, all 
patients were given a urethral catheter with a leg-bag directly 
after treatment. Patients were seen 1, 4 , 12, 26, and 52 weeks 
aftei treatment. Uroflowmetry with PVR volume, symptom 
scores, blood analysis, and urinalysis were repeated at each 
visit, Ultrasonography of the prostate was repeated at 12 and 
52 weeks. Finally, the urodynamic investigation was repeated 
26 weeks after treatment. Statistical analysis was done with 
the Student’s £ test ( a  =  0.05) and the Wilcoxon signed-rank 
test ( a  =  0 .05). Correlations were tested using the Pearson 
correlation ( a  =  0.05).
RESULTS
At baseline, 85 patients entered the study. At 1- 
year follow-up, 74 patients were available for anal- 
ysis. The follow-up scheme is presented in Figure 1.
Treatment
In 40 patients (47% ), additional intravenous se­
dation was necessary during treatment. None of
the treatments had to be stopped before 60 
minutes, nor did the energy level have to be re­
duced, The total am ount of energy delivered to the 
prostate ranged from 50.0 to 208.9 kj (m ean  ±  SD 
154.7 ±  36 .4). In  3 patients (3 ,5% ), it was no t 
possible to insert a transurethral catheter im m e­
diately after treatment, so a suprapubic catheter 
was inserted.
S u b j e c t i v e  Results ( S y m p t o m  Scores)
The complete group showed significant changes 
in both symptom scores. The m ean M adsen sym p­
tom score decreased by 58% at the 12-m onth fol­
low-up. W ith an initial im provem ent from a m ean 
±  SD of 13.9 ±  3.6 at baseline to 6.7 ±  4.6 at 3 
months, stabilizing occurred at 5.7 ±  4.6 at 6 
months and 5.8 ±  4.7 at the l~year follow-up. 
Comparable changes were noticed in the IPSS 
scores. The mean ( ±  SD) IPSS at baseline of 17.6 
±  6.0 decreased to 9.2 ±  6.4 at 3 m onths, 8.5 ±
6.5 at 6 months, and 8.0 ±  5.8 at the 1-year follow- 
up, indicating a m ean IPSS decrease by 55% at 1 
year (Fig. 2 ) .
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TABLE II. Percentage improvement and mean values of improvement of baseline parameters 5 
months after treatment
Baseline M ad sen IPSS Q m ax (mL/s)
pdet a t  Qm ax 
(cm H20 )
P a r a m e te r n % M ean  ± SD % M ean ± SD % M ean ± SD % M ean ± SD
M adsen <  15 51 48 5.6 ± 4 .4 40 6.7 ± 7 .3 88 6.5 ± 7.0 32 27.1 ± 27.7
M adsen ^  15 34 56 9.8 ± 5.1 48 11.0 ± 8 . 4 69 5.6 ± 6.6 31 21.5  ± 28 .4
Qmax s  12 26 64 9.5 ± 4 .8 59 11.3 ± 6 . 3 39 5.3 ± 5.5 36 23.4  t  29 .9
Qmax <  12 
P ros ta te  volume (cm5)
59 45 6.3 ± 5 .0 36 7 .2  ± 8 . 4 99 6.6 ± 7.3 30 25.3  ± 27 .5
s  40
Pros ta te  volume (cm5)
62 54 7.7 ± 5 .0 45 8 .6  ± 7.2 84 6.7 ± 7.3 39 2 9 .5  i  28 .9
<  40 23 43 6.2 ±  5.3 38 8.0 ± 9 .9 72 4 .9  ± 5.2 13 13.5 ± 22.1
linPURR 3 52 58 8,1 ± 4 .6 50 9 .4  ± 7.1 98 7.3 ± 7.3 44 36 .5  ± 24 .8
linPURR <  3 
linPURR ;> 3 and 
p ro s ta te  volume
31 40 6.2 ± 5.7 33 7.1 ± 9.3 53 4 .5  ± 5 .8 9 6.3. ± 17.3
(cm3) ^  40  40
K e y : IPSS = international Prostate Symptom
62
Scorc;
8 .6  ± 4.3
linPURR — lineari zt
53 9 .9  ± 6.3 102
:à passive i m ' t J m i l  r é s i s t a n t e  relation.
>
r-HOCO 46 39.0 ± 26.4
O b j e c t i v e  R e s u l t s
Voiding Parameters. For the complete group, the 
m ean m axim um  flow rate ( ±  SD ) showed signif-
±  3,3 m L /s at base­
rate (P Liei at Qm ax) before and 6 m onths after 
TUMT using the linPURR-nomogram for obstruc­
tion, At baseline, 46 patients (65% of 71) could 
be considered obstructed, with a linPURR of 3 or 
more. Using the linPURR classification for ob­
struction, 36 of these 46 patients (78% ) can no 
and 14.9 ±  6,7 m L /s  at 1-year follow-up. Similar longer be considered obstructed 6 months after 
im provem ents were noticed in the PVR and voided treatment.
icant im provem ent from 9.4 
line to 15.8 ±  7,0 m L/s at 3-m onth  follow-up and 
rem ained stable at 14.4 ±  6.7 m L /s at 6-month
percentage. A m ean ( ±  SD) PVR of 80 ±  88 mL 
at baseline improved to 26 ±  44 mL at 3 months, 
stabilizing at 28 ±  75 mL at 6 m onths and further
Transrectal Ultrasound Imaging o f the Prostate. At 
baseline, the mean prostate volume ( ±  SD) on u l­
trasonographic investigation was measured at 53.9 
im proving to 25 ±  35 mL after 1 year (Fig. 2). ±  22.8 mL (range 30 to 154). The repeated mea- 
The voided percentage improved from a mean ( ±  sûrem ent at 3 m onths showed an average volume 
SD) of 77 ±  18% at baseline to 92 ±  10% at 3 ( ±  SD) of 45,1 ±  19.1 mL (range 21 to 122), 
m onths, 93 ±  13% at 6 m onths, and 92 ±  11% thus indicating a significant volume reduction of 
after 1 year follow-up. 8.8 ±  12 mL (P < 0> 001). This reduction was con-
Urodynamic Investigation with Pressure-Fiow firmed at 52 weeks with a mean prostate volume 
Studies. At baseline, two investigations were ex- ( ±  SD) of 43.4 ±  19.3 mL (range 15 to 119). 
eluded because pressure-flow analysis was not Furtherm ore, in 35 patients of the available pa- 
available, due to unreliable recording of the void- tients at 3-m onth follow-up (42% of 8 3 ), a cavity 
ing phase; therefore, the urodynamic data of 83 could be observed (Fig. 4 ) .  The presence of a cav- 
patients were available. After 26 weeks, the urody- ity was positively correlated with improvement in 
namic investigation was repeated in 71 patients. In urinary performance and relief of outlet obstruc- 
t o t a l ,  8 patients refused a second investigation; the tion. The difference in Qmax improvement was
other 4 patients were the ones who were lost to significant (P =  0 .02): the mean improvement ( 
follow-up (Table 11). The urodynamic parameters SD) in Qmax is 8.5 ±  7.3 m L /s (from  9.4 to 17.9) 
significantly improved: the P ^ l at Qmax improved in patients with a cavity and 4.8 ±  5.4 m L/s in 
from a m ean ( ±  SD) of 63.6 ±  22.7 cm H20  at patients w ithout a cavity (from  9.7 to 14.5). In
accordance, there is greater relief of outlet obstruc­
tion in patients with a cavity (P =  0.002): the 
mean Paet at Qmax ( ±  SD) improves 36.8 ±  27.1 
cm H20  (from 70.4 to 33.6) in patients with a 
cavity and 17.7 ±  25.6 cm H20  (from  59.3 to 
41.6) in patients w ithout a cavity.
PSA Levels. The mean ( ±  SD ) PSA level at base-
baseline to 38.9 ±  15.7 cm H20  at 26 weeks; the 
PQ-Qm ax im proved from a m ean ( ±  SD) of 6.3 
±  2.3 m L /s  at baseline to 11.0 ±  5.4 m L/s at 26 
weeks; the linPURR im proved from a mean ( ±
SD) of 2.9 ±  1.3 at baseline to 1.3 ±  1.0 at 26
weeks.
Figure 3 gives a graphical representation of 
changes in  detrusor pressure at m axim um  flow line was 5,0 ±  3.3 ng/mL (range 0.5 to 14), and
UROLOGY 48 (3), 1996 419
nV'
;0>m
.0 ;
4?%Í I 
1  ¿Hi.....
.<*. V<<
f
I
£
v t
$
M
711
0
/>
:!i
M*
>} ¿V
& n>
a
;?wv
*
4jr¿&¡
*
%
¿v>
&■
/Mis
M
â
ißtem
y-.
é&
".r% 
•¡íí^/jl 
' *
,0&
ïfyyi
>)*é%
ék
.$•
-hH?®
'¿(yy.
,:'fe
.Jlfe.
A
■ ÏW-
*
&>
,y«w
Â
là
S'...r/l-r.%>>•
Me$$k
0b,■Ai’fc
$k
AyXUrJi
$ &
â
.m
,4 æ
A OSI
4.W
£k
.á
.V
¿s*-
>•’?#
r7>
/j
Ê
/&feif-l
a
0 
>y/SÏ■ ?:v
4t
• íe*
A•M~r:
&il,#
V^;Ü)
Él
,-J
• ’J
■&
y.i
‘i' :<-*>'■U-ih
-m
nf£'>.
yjÿJj
■.(i
■y ■A■<>
$
V>
¡&
••A.
-Jh
»
À
H
W
'/>
«i
•i'
A>
i i
*&<4?
?r
0'
*
•xi
■Ü
.A
«?:•
vsv
-S»
'.i t*
W
■.i)y
•ii
Ifr
■r?
y t
Yi
•s*i
■>&'-
>5
-A
’A
•fr
V»
«>
W
«h
«
• #
• y
M ■ri
Jt ^il
l
$
;, íílíJ J Íí Vi: ^í-.-V Í-? Î-r^Vrÿf V r'r'-'JfríVíff » V>^ ¿ •«  ^ Vi ^AÏ,V
(•
?;
vs> >«¡,1 >li-
!
f *
»
• $
;
r,(,:/^ r^ír....>_.r • .¿â:- %:: r^ Vv::'/
•t: * $ ■ %  - mú -à\\® f
.il
I 
' §
/ ■
\
l i ^
',f .‘1
’S
«rrîüs^p;^ #  ,
lï.
i^ííhlííríft^ía«.
iHi
'?• Vìi
: %
\ m .
■ W :
■m
*
This mainly concerned patients with bigger pros­
tates and patients with severe outlet obstruction.
around 13 and the expected outcome around 4, 
with an overall improvement of around 65%.10 The
The m ost com m on complaints noted during the present study is comparable to these data, with an
time of an indwelling catheter were bladder average improvement of Madsen symptom score 
spasms with urine leakage past the catheter in
25%, perineal discomfort in 7%, and hem aturia in
76%. After rem oval of the catheter, 60% of patients
from 13.y at baseline to 5.8 at week 52, repre­
senting an overall improvement of 58%. Improve­
ments in IPSS show a similar decrease when com-
experienced temporary irritative complaints of ur- pared with other studies of minimally invasive 
gency and frequent micturition. These irritative treatment for BPO. These studies represent an en- 
complaints could successfully be treated with an- try level IPSS of around 20 with improvement to
ticholinergic medication (oxybutynin) sometimes 
in com bination w ith anti-inflammatory drugs (di-
around 7 at the 12-month follow-up, representing 
an improvement of 65%.23 The present study
c lo fenac). All patients received systemic antibiotic shows comparable results with a mean IPSS of 17.7 
prophylaxis (c o trimoxazol) prior to treatment at baseline and improvement to 8.0 at week 52,
with an overall improvement of 55%.
The improved efficacy of high-energy TUMT
that was continued  for 5 days. In 29% of patients, 
the antibiotics were resumed either because of
positive culture or empirically in the case of sub- compared with former low-energy protocols is 
stantial complaints. Six patients (7% of 85) de- mainly expressed in a significantly better outcome 
veloped epidydimitis after treatment. On average, in all objective parameters. The far-better urinary 
the treatm ent-related complaints ended 2 to 3 performance is expressed in changes in uroflow- 
weeks after treatment. In total, 18 of 85 patients me try, which demonstrates a substantial increase 
(21%) were using anticoagulants of w hom  5 (6% in maximum urinary flow rate with reduction of 
of 85) were using coum arin derivatives. One of PVR and an increase of voiding percentage. Im- 
these patients had  to be adm itted to the urology provements in maximum flow rate are now in the 
w ard  for b ladder rinsing because of blood clot re- range that is usually seen in patients treated with 
tention due to dysregulated anticoagulant medi- TURP or open prostatectomy.24,2:> Such an im­
provement can only contribute to a more durable 
effect in the long term if this is indeed based on 
relief of outlet obstruction. Previous studies on 
urodynamic changes after TUMT with low energy 
levels reported little change in urodynamic ob­
struction parameters. This was not comparable to
cation.
COMMENT
Transurethral resection or open prostatectomy 
in the treatm ent of BPO still results in the best
sym ptom atic im provem ent and urinary perfor- urodynamic changes seen after TURP but seemed
mance. Various new surgical techniques are com­
parable in  their results.7"9 The major drawback of
to be founded on increased elasticity of the pros­
tatic urethra .26 On the contrary, high-energy
m ost of these treatments is that hospital admission TUMT can achieve TURP-like urodynamic relief 
and  anesthesia are still necessary. Although TUMT of obstruction, which in the present study is evi- 
does no t result in TURP-like objective improve- dently shown in the improvement of the urody-
ment, the question was raised w hether it was nec­
essary to reach the “supranorm al” flow rates
namic obstruction parameters. In 78% of patients 
who could be considered obstructed at baseline,
achieved w ith TURP since age-matched asympto- outlet obstruction is relieved. This substantial im­
provem ent is best illustrated by the changes in pre­
treatment and post-treatment detrusor pressure at
matic patients appear to have a flow rate (13 mL/s) 
m ore comparable to that of T U M T 22 It appeared 
that the m echanism  of action using this lower-en-. m axim um  flow using the linPURR-nomogram 
e r g y  therm otherapy is substantially different from (Fig. 3 ) .  It shows a general trend from the ob- 
the volum e reduction and cavity formation ob- structed pretreatm ent region toward the unob­
tained w ith  TURP. However, this cavity formation structed region after treatment, although some pa- 
m ost likely contributes most to the durable effect tients rem ain obstructed. This shift is comparable
of TURP in the long term. Although this study 
does n o t concern a random ized study of TURP 
versus TUMT, it is the first report that shows that 
it is indeed possible to achieve TURP-like results 
w ith  an anesthesia-free procedure w ithout major 
post-treatm ent morbidity.
The symptomatic im provem ent obtained using 
TUMT in this study, expressed as the Madsen 
sym ptom  score, is in agreement w ith ranges pre­
viously reported. The entry level score is usually
to the changes found in patients who are treated 
with TURP.27
Further evidence of the substantial effect on 
prostate tissue produced by the high-energy 
TUMT is shown in the significant reduction of 
prostate volume at 1 year by a mean ( ±  SD) of
10.5 ±  12 cm 3, which represents an overall re­
duction ( ±  SD) of 19.4 ±  21.8%. Available studies 
on prostate volume decrease after TURP show a 
higher am ount of tissue (around  60%) removal.28
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Changes in PSA levels shortly after TUMT have 
always been associated with the amount of effect 
that microwave energy causes on prostate tissue. 
In TUMT versus sham studies, no rise of PSA was 
seen in the sham-arm, whereas the TUMT group 
showed increase to a mean of 25 ng/mL.29 In a 
retrospective responder versus nonresponder 
study, it was shown that responders to TUMT had 
a significantly higher rise of PSA 1 week after treat­
ment when compared with nonresponders.30 In 
the present study, the PSA levels rose to mean lev­
els of around 40 ng/mL. Interestingly, the present 
study shows a significant correlation between the 
decrease of PSA below baseline level and the 
am ount of prostate volume reduction that is 
achieved, which is in accordance with w hat is 
found after TURP.31 Tissue damage not only can 
result in prostate volume reduction but also in cav­
ity formation. Previous studies with lower energy 
TUMT failed to show this effect on the prostate. 
In contradistinction, the present study notes a cav­
ity, comparable to cavities that can be seen after 
TURP, in 42% of patients (Fig. 4 ). The absence of 
a cavity, however, does not necessarily imply 
worse treatment outcome. ¿\lthough the mean im­
provement of several parameters might be less, the 
standard deviations indicate a moderate am ount of 
variation. Therefore, good response can also be 
seen on an individual basis.
However, there is a price to be paid in terms of 
morbidity. The present trial showed that there is 
an increased morbidity, mainly consisting of a p ro­
longed catheterization time and irritative com­
plaints after treatment. Whereas patients treated 
with lower energy TUMT are reported to have a 
retention rate after treatment of approximately 
20%, all patients treated with the high-energy pro­
tocol needed a catheter for at least 1 week. Al­
though irritative complaints— such as frequency, 
urgency, dysuria, and hematuria— were also re­
ported with lower energy TUMT treatments, they 
are more frequent and pronounced during the first
2 to 4 weeks in patients with high-energy treat­
ments. Nevertheless, the high-energy treatments 
are still possible on an outpatient basis in a single 
1-hour session without the need for anesthesia. 
Moreover, in the present study with 74 patients 
followed up for at least 1 year, there were no ure­
thral strictures, no bladder neck contractures, and 
no stress incontinence.
As a consequence of a more effective treatment, 
the effect on ejaculatory performance is substan­
tially changed. Patients treated with low-energy 
TUMT report a 5% to 10% retrograde ejaculation 
after treatment; in the present trial, this occurred 
in 44%, with an additional 15% of patients re­
porting a diminished ejaculatory volume. These 
results indicate that the high-energy TUMT is also
capable of changing the bladder neck function, 
which, besides causing retrograde ejaculation, is 
probably responsible for better urinary perfor­
mance and reduction of bladder outlet obstruc­
tion. Finally, one also has to keep in m ind that a 
large num ber of patients who are unfit for surgery 
because of poor physical health profit from this 
ambulatory anesthesia-free therapy. In this study, 
the 12 patients in ASA 3 to 4 group all responded 
favorably.
Although objective and subjective im prove­
m ents all point to TURP-like results, not all pa­
tients experienced equal response. Previous clini­
cal results of low-energy TUMT showed clear 
distinction between patients who respond favora­
bly in both subjective and objective terms and  pa­
tients who do not respond at all. In a retrospective 
multicenter study of responders versus nonre­
sponders, it was concluded that none of the base­
line parameters (such  as prostate volume, uro- 
flowmetry results, or sym ptom  scores) were able 
to define the ideal patient for treatm ent and to pre­
dict the result of the treatm ent.30 In  another m u l­
ticenter study using urodynam ic parameters, it 
was concluded that, w ith pressure-flow study pa­
rameters, it was possible to identify the patients 
who would respond favorably.32 Data analysis with 
stratification of baseline parameters in the present 
study shows favorable results in patients w ith 
moderate to severe bladder outlet obstruction and 
bigger prostates (Table II).  Nevertheless, there 
still is considerable difference in treatm ent ou t­
come among individual patients. The clinical ben ­
efit appears to be related to the achieved in tra ­
prostatic temperatures that result from a complex 
interaction between the biologic response to m i­
crowaves and the pattern  of energy provided du r­
ing treatm ent in any individual.14 This in teraction 
is probably greatly dependent on prostate vascu­
larization and tissue com position of the p ros­
tate,33,34 Further research should, therefore, be di­
rected toward gaining better insight in these 
matters.
4
CONCLUSIONS
High-energy TUMT results in im proved objec­
tive outcome with comparable subjective response 
when compared w ith low-energy TUMT treat­
ments reported previously. Overall, the im prove­
m ent now attains results that are comparable w ith  
surgical resection of the prostate; bladder-outlet 
obstruction is similarly relieved. Nevertheless, 
stratification of baseline data showed im proved ef­
ficacy in patients w ith bigger and urodynam ically 
obstructed prostates. However, post-treatm ent 
morbidity is substantial and  should  be given m ore 
attention in future prospective random ized trials.
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